The product is disappearing into reorder rhythm: revenue is shifting from won-each-time to arriving-on-its-own, and the
The model's full reasoning — Q1 2022 call → NOWe need answer only YES or NO. Need evaluate transcript. Need see if management describes growing share of revenue arrives without new selling event through reorders/refills/renewals/repeat purchases/usage-driven billing/aftermarket/consumable pull-through/customers' standing routines, and that this self-arriving share has recently and visibly grown as proportion, grounded in observed current behavior, changing quality of revenue. Need parse transcript. Company OPKO Health. Diagnostics and pharma. They discuss BioReference, COVID testing, core diagnostic business, specialty testing, Scarlet Health digital at-home. Also ModeX acquisition, Pfizer milestones, Somatrogon launches. Need identify any mention of recurring revenue? Maybe "surveillance testing and ongoing testing for schools, cruise lines, sports industry" - that is repeat contracts? "COVID volume currently remains stable and steady on a day-to-day basis as a result of our surveillance testing and ongoing testing for schools, cruise lines, and the sports industry." That is repeat/standing routines? But is it growing share? They added new schools and ships. But not necessarily proportion of revenue? Also "Scarlet services... receiving added reimbursement from payers as specifically covered service for over 85 million patients... significant demand... digital health clients... Teladoc relationship." That could be recurring? But not described as self-arriving revenue proportion recently grown. Question asks specifically: "does management describe that a GROWING SHARE OF THE COMPANY'S REVENUE NOW ARRIVES WITHOUT A NEW SELLING EVENT ... AND that this self-arriving share has RECENTLY AND VISIBLY GROWN as a proportion of the business, with management grounding the shift in observed current behavior and treating it as changing the company's quality of revenue?" Need answer YES only if both halves present. Let's examine transcript for any mention of recurring revenue, reorders, etc. There is no explicit "recurring revenue" except maybe "ongoing testing" and "surveillance testing". Also "COVID volume currently remains stable and steady on a day-to-day basis as a result of our surveillance testing and ongoing testing for schools, cruise lines, and the sports industry.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
DUOT · Q4 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, through reorders, renewals, etc., and that this has recently and visibly grown as a ...
QTRX · Q3 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through reorders, consumables, etc., and that this share has recently grown.
CYBR · Q3 2021 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through renewals, and that this has recently grown as a proportion.